ReiThera Srl, The Ragon Institute and IAVI Announce Collaboration to Advance Highly Networked T Cell HIV Vaccine Candidate Towards Phase I Clinical Evaluation
ReiThera Srl, the Ragon Institute of Mass General, MIT, and Harvard, and IAVI are pleased to announce a collaboration to develop a novel HIV vaccine candidate that will be composed of ReiThera’s GRAd vector and HIV T cell epitopes identified by the Ragon Institute, funded by the Bill & Melinda Gates Foundation.
- ReiThera Srl, the Ragon Institute of Mass General, MIT, and Harvard, and IAVI are pleased to announce a collaboration to develop a novel HIV vaccine candidate that will be composed of ReiThera’s GRAd vector and HIV T cell epitopes identified by the Ragon Institute, funded by the Bill & Melinda Gates Foundation.
- The Ragon Institute will lead GRAd-HIV preclinical development.
- IAVI will be the sponsor and execute a phase I clinical trial to evaluate the safety and immunogenicity of the GRAd-HIV vaccine candidate.
- Stefano Colloca, ReiThera’s Chief Technology Officer and co-Founder, said,
“We look forward to collaborating with IAVI and the Ragon Institute and continuing to advance our shared vaccine commitment to address the global challenges posed by HIV.